Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

Tirzepatide (Mounjaro®, Zepbound®)

Selected References:

  • Banerjee M, et al. 2026. Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort. Diabetes Obes Metab. May 7. doi: 10.1111/dom.70853. Online ahead of print. 
  • Diab H, et al. 2025. Tirzepatide (Zepbound) in human milk during periods of maternal dosing. Paper available as preprint (not peer reviewed). Preprint submitted to J Chromatogr B 2025. doi: 10.2139/ssrn.5387250. 
  • Duah J, Seifer DB. 2025. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. Reprod Biol Endocrinol. 23(1):2.  
  • Drummond R, et al. 2025. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. Am J Obstet Gynecol. 232(1):17-25. 
  • Howard MD, Allen SE. 2025. The use of GLP-1: receptor agonist medications for benign gynecology. Curr Opin Obstet Gynecol. 37(4):279-284. 
  • Food and Drug Administration. 2022. Mounjaro prescribing information. Retrieved on May 9 2024,from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf. Accessed June 2026. 
  • Food and Drug Administration. 2021. FDA nonclinical review of tirzepatide. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000PharmR.pdf. Accessed June 2026.  
  • Howard MD, Allen SE. 2025. The use of GLP-1: receptor agonist medications for benign gynecology. Curr Opin Obstet Gynecol. 37(4):279-284. 
  • Kettner J, et al. 2026. Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications. J Pharm Pract. 39(3):239-250.  
  • Sood A, et al. 2024. Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond. Expert Rev Clin Pharmacol. 17(3):235-246.  
  • Zepbound drug label. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&audience=consumer#modal-label-rss.  

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,200,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.